A multicentre, retrospective study to evaluate the efficacy of sorafenib versus sunitinib as a first-line therapy for patients with metastatic renal cell carcinoma

Next Previous
Trial Profile

A multicentre, retrospective study to evaluate the efficacy of sorafenib versus sunitinib as a first-line therapy for patients with metastatic renal cell carcinoma

Completed
Phase of Trial: Phase IV

Latest Information Update: 04 Apr 2016

At a glance

  • Drugs Sorafenib (Primary) ; Sunitinib (Primary)
  • Indications Renal cell carcinoma
  • Focus Therapeutic Use

    • Most Recent Events

    • 04 Apr 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top